Heparin treatment is associated with a delayed diagnosis of Alzheimer's dementia in electronic health records from two large United States health systems
Recent studies suggest that heparan sulfate proteoglycans (HSPG) contribute to the predisposition to, protection from, and potential treatment and prevention of Alzheimer's disease (AD). Here, we used electronic health records (EHR) from two different health systems to examine whether heparin t...
Gespeichert in:
| Veröffentlicht in: | Molecular psychiatry 2024-10 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | Molecular psychiatry |
| container_volume | |
| creator | Readhead, Benjamin Klang, Eyal Gisladottir, Undina Vandromme, Maxence Li, Li Quiroz, Yakeel T Arboleda-Velasquez, Joseph F Dudley, Joel T Tatonetti, Nicholas P Glicksberg, Benjamin S Reiman, Eric M |
| description | Recent studies suggest that heparan sulfate proteoglycans (HSPG) contribute to the predisposition to, protection from, and potential treatment and prevention of Alzheimer's disease (AD). Here, we used electronic health records (EHR) from two different health systems to examine whether heparin therapy was associated with a delayed diagnosis of AD dementia. Longitudinal EHR data from 15,183 patients from the Mount Sinai Health System (MSHS) and 6207 patients from Columbia University Medical Center (CUMC) were used in separate survival analyses to compare those who did or did not receive heparin therapy, had a least 5 years of observation, were at least 65 years old by their last visit, and had subsequent diagnostic code or drug treatment evidence of possible AD dementia. Analyses controlled for age, sex, comorbidities, follow-up duration and number of inpatient visits. Heparin therapy was associated with significant delays in age of clinical diagnosis of AD dementia, including +1.0 years in the MSMS cohort (P |
| doi_str_mv | 10.1038/s41380-024-02757-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3114500305</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3114500305</sourcerecordid><originalsourceid>FETCH-LOGICAL-c228t-a9f2da64299c1261924910782ee74498bd626f81519e9c03899f2a364dc9aa1f3</originalsourceid><addsrcrecordid>eNo9kctu1DAUhiNERS_wAiyQd7AJ-JrYy6oqbaVKLGjX1qlz0jFK4sHHo2p4E94Wp9OysGzL3_8fyV_TfBT8q-DKfiMtlOUtl7qu3vStedOcCN13rTG9fVvPyrhWC6uPm1OiX5yvj-Zdc6yc6l1n1Unz9xq3kOPCSkYoMy6FRWJAlEKEggN7imXDgA04wb5ehwiPS6LKpJGdT382GGfMn6kCazgCq104YSg5LTGwDcJUCzKGlAdiY04zK0-JTZAfkd0vcZ3xs9RR9MrSngrO9L45GmEi_PCynzX33y_vLq7b2x9XNxfnt22Q0pYW3CgH6LR0LgjZCSe1E7y3ErHX2tmHoZPdaIURDl2o3-ZqAFSnh-AAxKjOmi-H3m1Ov3dIxc-RAk4TLJh25JUQ2nCuuKmoPKAhJ6KMo9_mOEPee8H9qsQflPiqxD8r8Wvo00v_7mHG4X_k1YH6Byq0iW0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3114500305</pqid></control><display><type>article</type><title>Heparin treatment is associated with a delayed diagnosis of Alzheimer's dementia in electronic health records from two large United States health systems</title><source>SpringerLink Journals</source><creator>Readhead, Benjamin ; Klang, Eyal ; Gisladottir, Undina ; Vandromme, Maxence ; Li, Li ; Quiroz, Yakeel T ; Arboleda-Velasquez, Joseph F ; Dudley, Joel T ; Tatonetti, Nicholas P ; Glicksberg, Benjamin S ; Reiman, Eric M</creator><creatorcontrib>Readhead, Benjamin ; Klang, Eyal ; Gisladottir, Undina ; Vandromme, Maxence ; Li, Li ; Quiroz, Yakeel T ; Arboleda-Velasquez, Joseph F ; Dudley, Joel T ; Tatonetti, Nicholas P ; Glicksberg, Benjamin S ; Reiman, Eric M</creatorcontrib><description>Recent studies suggest that heparan sulfate proteoglycans (HSPG) contribute to the predisposition to, protection from, and potential treatment and prevention of Alzheimer's disease (AD). Here, we used electronic health records (EHR) from two different health systems to examine whether heparin therapy was associated with a delayed diagnosis of AD dementia. Longitudinal EHR data from 15,183 patients from the Mount Sinai Health System (MSHS) and 6207 patients from Columbia University Medical Center (CUMC) were used in separate survival analyses to compare those who did or did not receive heparin therapy, had a least 5 years of observation, were at least 65 years old by their last visit, and had subsequent diagnostic code or drug treatment evidence of possible AD dementia. Analyses controlled for age, sex, comorbidities, follow-up duration and number of inpatient visits. Heparin therapy was associated with significant delays in age of clinical diagnosis of AD dementia, including +1.0 years in the MSMS cohort (P < 0.001) and +1.0 years in the CUMC cohort (P < 0.001). While additional studies are needed, this study supports the potential roles of heparin-like drugs and HSPGs in the protection from and prevention of AD dementia.</description><identifier>ISSN: 1359-4184</identifier><identifier>ISSN: 1476-5578</identifier><identifier>EISSN: 1476-5578</identifier><identifier>DOI: 10.1038/s41380-024-02757-5</identifier><identifier>PMID: 39379683</identifier><language>eng</language><publisher>England</publisher><ispartof>Molecular psychiatry, 2024-10</ispartof><rights>2024. The Author(s).</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c228t-a9f2da64299c1261924910782ee74498bd626f81519e9c03899f2a364dc9aa1f3</cites><orcidid>0000-0001-9714-8244 ; 0000-0003-4353-9965 ; 0000-0002-0705-3696</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39379683$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Readhead, Benjamin</creatorcontrib><creatorcontrib>Klang, Eyal</creatorcontrib><creatorcontrib>Gisladottir, Undina</creatorcontrib><creatorcontrib>Vandromme, Maxence</creatorcontrib><creatorcontrib>Li, Li</creatorcontrib><creatorcontrib>Quiroz, Yakeel T</creatorcontrib><creatorcontrib>Arboleda-Velasquez, Joseph F</creatorcontrib><creatorcontrib>Dudley, Joel T</creatorcontrib><creatorcontrib>Tatonetti, Nicholas P</creatorcontrib><creatorcontrib>Glicksberg, Benjamin S</creatorcontrib><creatorcontrib>Reiman, Eric M</creatorcontrib><title>Heparin treatment is associated with a delayed diagnosis of Alzheimer's dementia in electronic health records from two large United States health systems</title><title>Molecular psychiatry</title><addtitle>Mol Psychiatry</addtitle><description>Recent studies suggest that heparan sulfate proteoglycans (HSPG) contribute to the predisposition to, protection from, and potential treatment and prevention of Alzheimer's disease (AD). Here, we used electronic health records (EHR) from two different health systems to examine whether heparin therapy was associated with a delayed diagnosis of AD dementia. Longitudinal EHR data from 15,183 patients from the Mount Sinai Health System (MSHS) and 6207 patients from Columbia University Medical Center (CUMC) were used in separate survival analyses to compare those who did or did not receive heparin therapy, had a least 5 years of observation, were at least 65 years old by their last visit, and had subsequent diagnostic code or drug treatment evidence of possible AD dementia. Analyses controlled for age, sex, comorbidities, follow-up duration and number of inpatient visits. Heparin therapy was associated with significant delays in age of clinical diagnosis of AD dementia, including +1.0 years in the MSMS cohort (P < 0.001) and +1.0 years in the CUMC cohort (P < 0.001). While additional studies are needed, this study supports the potential roles of heparin-like drugs and HSPGs in the protection from and prevention of AD dementia.</description><issn>1359-4184</issn><issn>1476-5578</issn><issn>1476-5578</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNo9kctu1DAUhiNERS_wAiyQd7AJ-JrYy6oqbaVKLGjX1qlz0jFK4sHHo2p4E94Wp9OysGzL3_8fyV_TfBT8q-DKfiMtlOUtl7qu3vStedOcCN13rTG9fVvPyrhWC6uPm1OiX5yvj-Zdc6yc6l1n1Unz9xq3kOPCSkYoMy6FRWJAlEKEggN7imXDgA04wb5ehwiPS6LKpJGdT382GGfMn6kCazgCq104YSg5LTGwDcJUCzKGlAdiY04zK0-JTZAfkd0vcZ3xs9RR9MrSngrO9L45GmEi_PCynzX33y_vLq7b2x9XNxfnt22Q0pYW3CgH6LR0LgjZCSe1E7y3ErHX2tmHoZPdaIURDl2o3-ZqAFSnh-AAxKjOmi-H3m1Ov3dIxc-RAk4TLJh25JUQ2nCuuKmoPKAhJ6KMo9_mOEPee8H9qsQflPiqxD8r8Wvo00v_7mHG4X_k1YH6Byq0iW0</recordid><startdate>20241008</startdate><enddate>20241008</enddate><creator>Readhead, Benjamin</creator><creator>Klang, Eyal</creator><creator>Gisladottir, Undina</creator><creator>Vandromme, Maxence</creator><creator>Li, Li</creator><creator>Quiroz, Yakeel T</creator><creator>Arboleda-Velasquez, Joseph F</creator><creator>Dudley, Joel T</creator><creator>Tatonetti, Nicholas P</creator><creator>Glicksberg, Benjamin S</creator><creator>Reiman, Eric M</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9714-8244</orcidid><orcidid>https://orcid.org/0000-0003-4353-9965</orcidid><orcidid>https://orcid.org/0000-0002-0705-3696</orcidid></search><sort><creationdate>20241008</creationdate><title>Heparin treatment is associated with a delayed diagnosis of Alzheimer's dementia in electronic health records from two large United States health systems</title><author>Readhead, Benjamin ; Klang, Eyal ; Gisladottir, Undina ; Vandromme, Maxence ; Li, Li ; Quiroz, Yakeel T ; Arboleda-Velasquez, Joseph F ; Dudley, Joel T ; Tatonetti, Nicholas P ; Glicksberg, Benjamin S ; Reiman, Eric M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c228t-a9f2da64299c1261924910782ee74498bd626f81519e9c03899f2a364dc9aa1f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Readhead, Benjamin</creatorcontrib><creatorcontrib>Klang, Eyal</creatorcontrib><creatorcontrib>Gisladottir, Undina</creatorcontrib><creatorcontrib>Vandromme, Maxence</creatorcontrib><creatorcontrib>Li, Li</creatorcontrib><creatorcontrib>Quiroz, Yakeel T</creatorcontrib><creatorcontrib>Arboleda-Velasquez, Joseph F</creatorcontrib><creatorcontrib>Dudley, Joel T</creatorcontrib><creatorcontrib>Tatonetti, Nicholas P</creatorcontrib><creatorcontrib>Glicksberg, Benjamin S</creatorcontrib><creatorcontrib>Reiman, Eric M</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Readhead, Benjamin</au><au>Klang, Eyal</au><au>Gisladottir, Undina</au><au>Vandromme, Maxence</au><au>Li, Li</au><au>Quiroz, Yakeel T</au><au>Arboleda-Velasquez, Joseph F</au><au>Dudley, Joel T</au><au>Tatonetti, Nicholas P</au><au>Glicksberg, Benjamin S</au><au>Reiman, Eric M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Heparin treatment is associated with a delayed diagnosis of Alzheimer's dementia in electronic health records from two large United States health systems</atitle><jtitle>Molecular psychiatry</jtitle><addtitle>Mol Psychiatry</addtitle><date>2024-10-08</date><risdate>2024</risdate><issn>1359-4184</issn><issn>1476-5578</issn><eissn>1476-5578</eissn><abstract>Recent studies suggest that heparan sulfate proteoglycans (HSPG) contribute to the predisposition to, protection from, and potential treatment and prevention of Alzheimer's disease (AD). Here, we used electronic health records (EHR) from two different health systems to examine whether heparin therapy was associated with a delayed diagnosis of AD dementia. Longitudinal EHR data from 15,183 patients from the Mount Sinai Health System (MSHS) and 6207 patients from Columbia University Medical Center (CUMC) were used in separate survival analyses to compare those who did or did not receive heparin therapy, had a least 5 years of observation, were at least 65 years old by their last visit, and had subsequent diagnostic code or drug treatment evidence of possible AD dementia. Analyses controlled for age, sex, comorbidities, follow-up duration and number of inpatient visits. Heparin therapy was associated with significant delays in age of clinical diagnosis of AD dementia, including +1.0 years in the MSMS cohort (P < 0.001) and +1.0 years in the CUMC cohort (P < 0.001). While additional studies are needed, this study supports the potential roles of heparin-like drugs and HSPGs in the protection from and prevention of AD dementia.</abstract><cop>England</cop><pmid>39379683</pmid><doi>10.1038/s41380-024-02757-5</doi><orcidid>https://orcid.org/0000-0001-9714-8244</orcidid><orcidid>https://orcid.org/0000-0003-4353-9965</orcidid><orcidid>https://orcid.org/0000-0002-0705-3696</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1359-4184 |
| ispartof | Molecular psychiatry, 2024-10 |
| issn | 1359-4184 1476-5578 1476-5578 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3114500305 |
| source | SpringerLink Journals |
| title | Heparin treatment is associated with a delayed diagnosis of Alzheimer's dementia in electronic health records from two large United States health systems |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T01%3A17%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Heparin%20treatment%20is%20associated%20with%20a%20delayed%20diagnosis%20of%20Alzheimer's%20dementia%20in%20electronic%20health%20records%20from%20two%20large%20United%20States%20health%20systems&rft.jtitle=Molecular%20psychiatry&rft.au=Readhead,%20Benjamin&rft.date=2024-10-08&rft.issn=1359-4184&rft.eissn=1476-5578&rft_id=info:doi/10.1038/s41380-024-02757-5&rft_dat=%3Cproquest_cross%3E3114500305%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3114500305&rft_id=info:pmid/39379683&rfr_iscdi=true |